Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients (CLOTT)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Lancaster General Hospital
University of Florida
Medical University of South Carolina
Portland VA Medical Center
Stanford University
Johns Hopkins University
Massachusetts General Hospital
The University of Texas Health Science Center, Houston
Medical College of Wisconsin
Oregon Health and Science University
Christiana Care Health Services
San Francisco General Hospital
University of Utah
Carolinas Medical Center
Information provided by (Responsible Party):
Scripps Health
ClinicalTrials.gov Identifier:
NCT01890044
First received: June 26, 2013
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

Venous thromboembolism (VTE) remains a leading cause of death in trauma patients. Based on the EAST Management Guidelines for the prevention of VTE in trauma patients, a number of research questions could be addressed by a thorough current literature review combined with a multicenter concurrent analysis. This proposal seeks to create a data registry of trauma patients from multiple trauma centers around the United States that will serve as a platform for the study of VTE.


Condition
Venous Thromboembolism
Pulmonary Embolus
Deep Vein Thrombosis

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 30 Days
Official Title: Consortium of Leaders in the Study Of Traumatic Thromboembolism (CLOTT): A Multicenter Registry for Determining the Comparative Effectiveness of Risk Assessment, Prophylaxis, Surveillance, and Treatment of Venous Thromboembolism in Trauma Patients

Resource links provided by NLM:


Further study details as provided by Scripps Health:

Primary Outcome Measures:
  • Venous Thromboembolism (VTE) [ Time Frame: 30 Days from time of hospital admission ] [ Designated as safety issue: Yes ]
    VTE is the clinical spectrum of disease including Deep Vein Thrombosis (DVT) and Pulmonary Embolus.


Secondary Outcome Measures:
  • Complications following VTE care [ Time Frame: 30 days from date of hospital addmission ] [ Designated as safety issue: Yes ]
    The standard prophylaxis of, and care for diagnosed VTE disease in trauma patients involves medications and devices which themselves have inherent risk. These risks/possible complications include: Death, bleeding, heparin induced thrombocytopenia, and complications associated with the insertion or removal of inferior vena caval filters.


Estimated Enrollment: 10000
Study Start Date: August 2013
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Trauma patients at moderate to highest risk for VTE
Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.

  Hide Detailed Description

Detailed Description:

The VTE related research questions, identified by the EAST Management Guidelines as needing further study, are:

  1. While numerous risk factors for VTE have been identified and reported, there are only 2 that have Level 1 evidence to support them—spine fracture and spinal cord injury. Many of the other reported risk factors were identified in studies that did not have protocols for surveillance, reported only on patients with symptoms, or used data from large administrative databases such as the National Trauma Data Bank4. It has also been shown that the frequency of diagnosis of deep venous thrombosis (DVT) increases when more duplex imaging of the extremities is undertaken5. Thus, if an aggressive concurrent surveillance program for DVT and aggressive work up of suspected pulmonary embolism (PE) is undertaken:

    1. Are there unknown or under-reported risk factors?
    2. Is there a hierarchy of risk among the factors? For example, is a long bone fracture associated with a higher incidence of VTE than a closed head injury?
    3. Do all closed head injuries with an AIS>3 have the same degree of risk or is an epidural hematoma more risky than a subdural hematoma?
    4. What constitutes high and very high risk?
  2. What is the comparative efficacy and value6 of unfractionated heparin (UH), low molecular weight heparin (LMWH) and direct thrombin inhibitors (DTI) with or without associated mechanical prophylaxis (MP) in preventing VTE in trauma patients? In examining this question, the morbidity of these agents must be carefully determined, particularly with respect to intracranial injury and intra-abdominal solid viscus injury.
  3. In trauma patients who develop VTE what is the best treatment and for how long?
  4. Should all trauma patients who develop proximal deep venous thrombosis (pDVT) undergo a workup for thrombophilia or should this be based up the degree of "inverse risk" (inverse risk meaning a patient with a minor injury, who is thought to be at low risk, who develops pDVT)? Similarly, should trauma patients who develop pulmonary embolism (PE) undergo a workup for thrombophilia or should this be based up the degree of "inverse risk" [question 4 adds importance to answering questions 1a and 1b]?
  5. A recent meta-analysis of observational studies suggests that prophylactic inferior vena cava filters (PICVF) significantly reduce the risk of PE (OR: 0.09-0.49)7. The authors of the meta-analysis point out a number of methodological flaws with the studies selected for the analysis. Most importantly, all were retrospective studies with historical controls and the use of pharmacologic prophylaxis was not uniform among the studies evaluated. Despite this report, there is continued significant practice variation in the use of PIVCF and the role of PIVCF in the care of trauma patients remains at question. Thus, if an aggressive concurrent surveillance program for DVT and aggressive work up of suspected PE is undertaken:

    1. Are all patients perceived to be at high risk for VTE who also have a relative or absolute contraindication to pharmacologic prophylaxis receiving a PIVCF?
    2. Do PIVCF reduce the risk of PE in trauma patients in whom risk adjustment has been done?
    3. Do PIVCF have value for the trauma patient at very high risk for VTE, the high risk trauma patient or the moderate risk trauma patient? In examining this question, the morbidity of PIVCF must be carefully determined, particularly with respect to their placement (including local complications at the insertion site, their migration and degree of tilt) and long-term complications.
  6. Because most DVT is asymptomatic the clinical examination is extremely insensitive. Therefore, surveillance of the lower extremity venous systems is necessary. However, the use of routine surveillance is controversial. It is also known that venous duplex exams, while very accurate in the symptomatic patient, can be quite insensitive in the asymptomatic patient. In addition, surveillance scanning is hampered by external fixators and wounds (as many as 30% of extremities cannot be scanned for this reason10. Finally, it is not uncommon for trauma patients to have a PE (even a fatal PE) with negative followup surveillance of the lower extremity (LE) and upper extremity (UE) venous systems. This would suggest either that the surveillance duplex was inaccurate, or the clot arose in a vein that could not be well interrogated by duplex (i.e., the hypogastric), or that the clot arose de novo in the pulmonary artery11. Thus, if an aggressive concurrent surveillance program for DVT and aggressive work up of suspected PE is undertaken:

    1. Does "protocolized" surveillance (surveillance of asymptomatic patients) have value? In other words, does the quality of the outcome (determining the presence of asymptomatic thrombus in the vein of an extremity) justify the cost?
    2. What constitutes the most effective protocol in terms of when the initial scan should be done and the frequency of subsequent scans?
    3. What is the fate of peroneal vein and tibial vein clot? Does it vary depending on the degree of risk (i.e., more likely to propagate in patients who are at the highest risk compared to patients with lower risk)? The same question could be posed with respect to soleal vein or gastrocnemius vein clot.
    4. Does magnetic resonance venography have a role in high risk trauma patients as a surveillance modality—particularly those with pelvic fractures or severe LE fractures that cannot be reliably scanned?
    5. Does contrast venography have a role in high risk trauma patients as a surveillance modality, particularly in patients who have had a PE and who have a negative duplex?
    6. Since it has been shown by numerous authors that there is surveillance bias with regard to the diagnosis of DVT (i.e., the diagnosis is more often reported at hospitals doing more frequent scanning5, does the frequency of the diagnosis of PE increase as the number of chest CT angiograms are performed?
  7. Recent studies suggest an association between local14 or systemic11 inflammation and pulmonary thrombosis (perhaps not embolism). Is there an increased risk of DVT or primary pulmonary thrombosis for trauma patients who have an associated inflammatory process such as sepsis, urinary tract infection (UTI) or pneumonia (PNA)? What constellation of local injury puts a patient at risk for pulmonary thrombosis?

We are proposing to perform an extensive literature review on each of these questions to produce a state of the art publication in follow-up of the EAST Management Guidelines and to provide a platform for a multicenter study of each or all of these questions.

METHODS

  1. Literature Review. The literature review of each question will cover the period 1989-2011. The year 1989 was selected because that was the year of the last major literature review (the exception is the review by Rogers (ref) who authored the EAST Management Guidelines). Each review will begin with a literature search performed under the guidance of a medical librarian using appropriate key words and MeSH (medical subject headings). The bibliography of key articles will also be reviewed for pertinent literature. Authors of the review will select criteria relevant to the question that will be used to select articles to be used in the review.
  2. Center Selection. Centers selected for inclusion in the multicenter studies must have an interest in VTE, a research and publication track record on the subject, and be willing to participate by submitting their de-identified data to Scripps Mercy. The centers will be selected by Drs. Steven Shackford and Frederick Rogers, recognized experts in the field of VTE in trauma.
  3. Study Design. Observational cohort.
  4. Patients. All adult (age > 18) trauma patients admitted to each of the centers with an expected length of stay (LOS) of > 72 hours will be eligible for inclusion.
  5. Interventions. Each patient will undergo a risk assessment for VTE in compliance with the Surgical Care Improvement Program (SCIP-VTE 1 & 2)12, which is currently being done by most hospitals. Provided that there are no absolute or relative contraindications, each patient will receive appropriate VTE prophylaxis in compliance with the SCIP for the duration of their hospitalization. The use of SCIP is a condition of participation in Medicare and poses no additional risk and no alteration in care of trauma patients. Surveillance for VTE will not be affected by participation in the study, but will be whatever is usual and customary for the participating institution. Similarly, the management of patients who develop VTE will not be affected by participation in the study, but will be whatever is usual and customary for the participating institution.
  6. Data. The following data will collected concurrent with care:

    a. Institutional: i. Unique hospital identifier ii. Type: <drop down, 3 choices>

  1. Teaching, formal university affiliation
  2. Teaching, free-standing surgical residency training program
  3. Non-teaching (all not included in the above) iii. Participation in the American College of Surgeons (ACS) Trauma Center Verification Program: <drop down>
  1. If yes, Level _____ <input limit- 1, 2 or 3>
  2. No iv. Average number of trauma patients admitted annually over each of the last 5 years٭: <numeric input, limit 0-10,000>

1. Year 1-______ Year 2-______ Year 3-______ Year 4-______ Year 5-______

v. VTE surveillance program description: <drop down choices with free text for answer # 5>

  1. None
  2. Duplex weekly
  3. Duplex twice weekly
  4. Duplex once during admission
  5. Selective Surveillance (please describe, limit to 250 characters): _________________________________________________ vi. Participation in the ACS National Trauma Data Bank (may have more than one selection): <drop down>
  1. Yes
  2. No
  3. Participation in a home grown, regional or statewide registry vii. Do you have a computerized order entry system with clinical decision support? If so, please specify (250 characters).

<free text>________________________________________________________

b. Patient: i. Demographics and generic trauma-related data:

  1. Age (in years)<limit 0-110> ٭
  2. Gender <Check box>

    1. Male
    2. Female
  3. Race/Ethnicity <drop down>

    1. Caucasian
    2. African American
    3. Hispanic/Latino
    4. Asian
    5. Pacific Islander
    6. Native American
    7. Unknown ethnicity/Other
  4. Admission vital signs

    1. Systolic Blood Pressure (SBP) <limit input: 0-300>
    2. Pulse Rate <limit: 0-300>
    3. Temperature <limit: 0-45 C >
  5. Shock (indicate all that apply):

    a. SBP <80 mmHg (Y/N) b. Base deficit > -5 (Y/N) c. Arterial or venous lactate > 4 (Y/N)

  6. Glasgow coma scale (GCS) (at time of admission) <limit: 3-15>
  7. Height (in meters) <limit 0-3>
  8. Weight (in Kg) <limit: 0-300>
  9. Injury Severity Score <limit: 1-75>
  10. Mechanism: <check box>

    1. Blunt
    2. Penetrating
  11. Probability of survival using the Trauma score- Injury Severity Score (TRISS) methodology <limit: 0-1>
  12. Head Abbreviated injury score (AIS) <limit: 0-6>
  13. Lower extremity AIS <limit: 0-6>
  14. Chest AIS <limit: 0-6>
  15. Abdominal AIS <limit: 0-6>
  16. Spine AIS <limit: 0-6>
  17. List of all injuries٭ (No text! Coded from Vermont Performance Improvement Manual) (n=1-∞)
  18. List of all complications/morbidities not present on admission٭ (No text! Coded from Vermont Performance Improvement Manual) (n=1-∞)
  19. List of all surgical procedures (No text! current procedural terminology (CPT) or ICD-9 codes) ii. Pertinent past medical history (existing prior to admission):
  1. History of PE (Y/N)
  2. History of DVT (Y/N)
  3. Any VTE in a first degree relative (Y/N)
  4. History of a thrombophilic disorder٭ (Y/N)
  5. History of concurrent cancer٭<yes / no, if yes then drop down menu> a. Hematopoietic b. Lymphatic c. Visceral d. Prostate e. Uterine f. Ovarian g. Breast h. Melanoma
  6. History of previous cancer٭<yes / no, if yes then drop down menu>

    a. Hematopoietic b. Lymphatic c. Visceral d. Prostate e. Uterine f. Ovarian g. Breast h. Melanoma

  7. History of inflammatory bowel disease٭<Y/N>
  8. Hormone replacement therapy٭<Y/N>

    a. If yes, what agent? <free text>

  9. Contraceptive medications containing estrogen <Y/N>
  10. Pregnant or recently post-partum٭<Y/N>
  11. Smoking, current<Y/N>

    a. If yes, estimate pack years:_______ <limit: 1-1000>

  12. Previous smoker, but quit. <Y/N>

    a. If yes, estimate pack years:_______ <limit: 1-1000>

  13. Ambulatory prior to admission (Y/N)?٭
  14. Taking Warfarin, Xa inhibitor, DTI, antiplatelet, or ASA (325mg) at time of admission?

    a. If yes, was it held temporarily following admission?٭ c. Hospital Course٭ (TREK=Date and [Military time] of each occurrence) <expandable data set to include each occurrence of pt movement to new care > i. Resuscitation bay ii. ICU1 iii. ICU2 iv. ICU… v. OR1 vi. OR2 vii. OR… viii. Ward ix. Morgue x. Discharge form hospital

    d. Treatment related data (recorded DAILY) i. Ventilation ٭ (Y/N)

1. If yes, total ventilator days _______ <limit: 1-365> ii. Transfusion in last 24 hrs٭ (Y/N) (if yes, drop down below to indicate units given)

  1. Fresh frozen plasma (FFP) _________ <limit: 1-100>
  2. Packed Red Blood Cell (PRBC) _________<limit: 1-100>
  3. Prothrombin Complex Concentrate (PCC) ________<limit: 1-100>
  4. Cryoprecipitate __________<limit: 1-100>
  5. Platelets __________<limit: 1-100> iii. Central venous catheter placement in last 24 hrs (if yes, site)
  1. Subclavian (R/L)
  2. Femoral (R/L)
  3. Internal jugular (R/L) iv. Infectious complications in preceding 24 hours <drop down>
  1. UTI
  2. Pneumonia
  3. Surgical site infection٭ a. Superficial b. Deep
  4. Intra-abdominal abscess
  5. Septicemia
  6. Other: ___________ (50 characters) <free text> v. Activity status <drop down>
  1. Ambulatory
  2. Bed rest
  3. Non-weight bearing

    a. One leg b. Both legs

    e. VTE related data (recorded DAILY):

  1. Patient risk level٭<drop down>

    1. Very high
    2. High
    3. Moderate
    4. Low
  2. Lower extremity duplex ultrasound (recorded on days performed):

    a. Ordered for (Select one of the following): <drop down> i. Institutional surveillance ii. Symptoms b. Adequately imaged sites: (each site: Yes/No/Not attempted) i. Right Gastrocnemius/soleus imaged ii. Right Tibials/peroneal imaged iii. Right Popliteal imaged iv. Right Femoral imaged v. Right External iliac imaged vi. Left Gastrocnemius/soleus imaged vii. Left Tibials/peroneal imaged viii. Left Popliteal imaged ix. Left Femoral imaged x. Left External iliac imaged

  3. Upper extremity duplex ultrasound (recorded on days performed):

    a. Ordered for (Select one of the following): <drop down> i. Institutional surveillance ii. Symptoms b. Adequately imaged sites: (each site: Yes/No/Not attempted) i. Right Basilic/Cephalic imaged ii. Right Subclavian/Axillary imaged iii. Right Brachial imaged iv. Right Internal Jugular imaged v. Left Basilic/Cephalic imaged vi. Left Brachial imaged vii. Left Subclavian/Axillary imaged viii. Left Internal Jugular imaged

  4. Indicate cause of inadequate imaging (upper or lower extremity): <drop down>

    a. Patient uncooperative/refused b. Plaster immobilizer c. External fixators d. Wounds or dressings e. Other: ____________________________ (limit to 50 characters) <free text>

  5. VTE events٭ (indicate all that apply, recorded DAILY): <check boxes>

    a. Intramuscular clot (gastrocnemius or soleus) b. Tibial or peroneal vein clot c. Below knee popliteal vein clot d. Above knee popliteal vein clot e. Femoral vein clot f. Iliac vein clot g. Cephalic or basilic vein clot h. Brachial vein clot i. Axillary vein clot j. Jugular vein clot k. Subclavian vein clot l. Innominate vein clot i. Method of detection? <if box checked, free text> m. IVC clot i. Method of detection? <if box checked, free text> n. Mesenteric vein clot i. Method of detection? <if box checked, free text> o. Portal vein clot i. Method of detection? <if box checked, free text> p. Pulmonary embolism: i. Method of detection: <drop down>

  1. CT-PA
  2. V/Q scan
  3. Pulmonary angiogram
  4. Incidental (consequent to imaging for another problem)
  5. Autopsy
  6. Other: __________________(limit to 50 characters) <free text> ii. Detail of clot (indicate all that apply) <drop down>
  1. saddle
  2. lobar
  3. segmental
  4. sub-segmental
  5. unclassified
  6. Work up for suspected VTE (recorded DAILY) in past 24 hours:

    a. INDICATIONS-all that apply: <check boxes> i. Extremity pain ii. Extremity swelling iii. Extremity discoloration iv. Shortness of breath/tachypnea v. O2 saturation decrease vi. Tachycardia vii. Chest pain viii. Other_________________ (limit to 50 characters) <free text> b. Duplex: (Y/N) if Y, result: POS/NEG c. Venography: (Y/N) if Y; result POS/NEG d. CT-PA protocol: (Y/N) if Y; result POS/NEG e. Pulmonary angiogram:(Y/N) if Y; result POS/NEG f. Ventilation/perfusion scan: (Y/N) if Y; result POS/NEG g. Diagnosed VTE by clinical suspicion (explain, 500 characters): ____________________________________ <free text>

  7. Treatment for VTE related event (recorded DAILY): <if no, skip question; if yes drop menu> a. Heparin drip b. Enoxaparin c. Fondaparinux d. Rivoraxaban e. Coumadin f. Agatroban g. Inferior vena cava filter (Y/N) <if yes> rationale: <drop down> i. PE on adequate therapeutic anticoagulation ii. Hemorrhagic complication (see below) iii. Contraindication to anticoagulation (specify): _____________________ (limit to 200 characters) <free text> iv. If therapeutic filter placed:
  1. Insertion site <drop down>

    1. R/L Femoral vein
    2. R/L Internal Jugular vein
    3. R/L Subclavian vain
    4. Other: ______ (limit 50 characters)

8. Complications (recorded DAILY on all patients): <check boxes for Y/N, if yes expands to answers below>

  1. HIT
  2. Evidence of GI bleeding:

i. None ii. Bloody gastric secretions or emesis iii. Guaiac positive stools or hematochezia iv. Other: _______ (limit 50 characters) <free text> c. Evidence of GU bleeding: i. None ii. Gross blood in urine iii. Other: _______ (limit 50 characters) <free text> d. Wound hematoma e. Hemorrhage from a recent wound٭ i. Major ii. Minor f. Transfusion during last 24 hours (rationale): <drop down> i. Gradual reduction in hemoglobin to our institutional transfusion trigger ii. Near out institutional trigger and going to surgery with expected blood loss iii. Hemorrhagic shock iv. Other: _________ (limit to 100 characters) <free text>

9. Prophylaxis (recorded DAILY):

a. Mechanical٭ (intermittent compression): <check Y/N; if checked Y; expand with answers below> i. Both legs below knee ii. One leg (rationale):

  1. Orthopedic device (i.e., plaster immobilizer, external fixators, etc)
  2. Wounds (i.e., dressings, wound vac, etc
  3. Other: ___ (limit to 100 characters) <free text> iii. None (rationale):
  1. Orthopedic device (i.e., plaster immobilizer, external fixators, etc)
  2. Wounds (i.e., dressings, wound vac, etc
  3. Other: ___ (limit to 100 characters) b. Pharmacologic:٭ <check Y/N; if checked Y; expand with answers below> i. Heparin
  1. Dose: (5000U, 7500U, other_______) (25 characters)
  2. Frequency: (Q8/Q12, other _______) (25 characters) ii. Low molecular weight heparin
  1. Dose: (30mg, 40mg, other_______) (25 characters)
  2. Frequency: (Q12, Daily, other _____) (25 characters) iii. Other pharmacologic prophylaxis agent
  1. Name ____________ (25 characters)
  2. Dose ____________ (25 characters)
  3. Frequency ________ (25 characters) iv. Missed/held doses in last 24 hours (Y/N)

1. Rationale for missed/held dose: ________ (250 characters) c. Prophylactic inferior vena cava (IVC) filter (recorded Daily): <drop down> i. None ii. Rationale for placement (Cannot receive pharmacologic prophylaxis because): <drop down>

  1. Hemorrhagic complication
  2. HIT
  3. Solid organ injury
  4. Closed head injury
  5. Spinal cord injury
  6. Pelvic fracture with hemorrhage٭
  7. Multiple long bone fractures
  8. Spine fracture
  9. Retroperitoneal hematoma
  10. Other____________ (50 characters) <free text> iii. Insertion site<drop down>
  1. R/L Femoral vein
  2. R/L Internal Jugular vein
  3. R/L Subclavian vein
  4. Other: _________ (50 characters) <free text>

10. IVC filter placement (prophylactic or therapeutic)

  1. If placed, filter type: <drop down>

    1. Cook Celect™ 2. Cook Tulip™ 3. Cook Bird's Nest™ 4. Bard Simon Nitinol™ 5. Bard G2™ 6. Bard Eclipse™ 7. Bard Meridian™ 8. Bard Denali™ 9. ALN filter™ 10. Cordis OptEase™ 11. Cordis TrapEase™ 12. Argon Option filter™ 13. SafeFlo™ 14. Vena Tech LGM™ 15. Vena Tech LP™ 16. Other:_______ (50 characters) <free text>

  2. If placed, location of placement: <drop down>

    1. Bedside
    2. Radiology
    3. OR
  3. Insertion site complications: <drop down> 1. Local hematoma 2. Local hemorrhage requiring intervention:

a. Transfusion b. Procedure 3. DVT at site 4. IVC occlusion 5. Device misplacement 6. Other__________ (50 characters) d. Complications: (Indicate days from insertion to occurrence)<check boxes, if checked Y; provide # day of occurrence as indicated>

  1. None
  2. Filter tilt _____ (day number or N/A)
  3. Migration ______ (day number or N/A)
  4. Caval thrombosis _____ (day number or N/A)
  5. Strut fracture _____ (day number or N/A)
  6. Pain ______ (day number or N/A)
  7. Extrusion of filter ______ (day number or N/A) e. Filter retrieval<drop down>

1. Unsuccessful, patient lost to followup 2. Unsuccessful, patient refused 3. Unsuccessful, attempted, but failed to retrieve filter 4. Technical success without any complication 5. Technical success with:

  1. Hemorrhage
  2. Hematoma
  3. Other_________ (50 characters) <free text>

f. Service inserting filter: <drop down>

  1. Interventional radiology
  2. Vascular surgery
  3. trauma /critical care
  4. other:___________ (50 characters) <free text>

7. Analysis. Patients will be stratified according to their perceived risk (based on the existing literature) on their first hospital day into one of the risk categories specified by the American College of Chest Physicians (ref). This initial risk assessment in the current basis for the determination of the need for prophylaxis. The effectiveness and morbidity of prophylaxis will be determined in the various risk categories concurrent with care. The effectiveness and value of surveillance protocols as well as the rationale for the use of prophylactic vena cave filters will be determined.

8. Patient Safety. Patients will remain anonymous; all patient identifiers will be purged from the data at the originating center. Patient care will NOT be affected in any way by participation in the study. Data recorded on paper will be kept in the Scripps Mercy Trauma Research Office in locked filed cabinets. Digital data will be kept on either encrypted disks or in computers requiring password access.

9. Importance. The results of this study will add greatly to our understanding of the comparative effectiveness of the prophylaxis, surveillance and treatment of VTE in trauma patients 10. Data Input/Quality Assurance. All data will be collected via a secure web based data collection tool (Research Electronic Data Capture - REDCap). Each participating institution will have a secure login access code to input de-identified patient information. REDCap allows data acquisition with set perimeters per question to ensure data quality. Limiters per response and questions with 'branching logic' points have been created with 'must answer' data protection elements enabling real time data quality assurance. Review of interim data will be periodic and based on the REDCap report building function. Missing data will be accessed and reported to the reporting data center for validation of values. Depending on the type of analysis performed with the data elements, individual missing data may be inputted or dropped from each of the final analysis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients admitted to the hospital for the care of traumatic injuries who have a moderate to highest level of VTE risk.

Criteria

Inclusion Criteria:

  • Admitted to the hospital for care of injuries
  • Have a greater than minimal (moderate to highest) level of VTE risk

Exclusion Criteria:

  • Discharged prior to 24 hours in hospital
  • Minimal VTE risk
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01890044

Locations
United States, California
Scripps Mercy Hospital
San Diego, California, United States, 92103
Sponsors and Collaborators
Scripps Health
Lancaster General Hospital
University of Florida
Medical University of South Carolina
Portland VA Medical Center
Stanford University
Johns Hopkins University
Massachusetts General Hospital
The University of Texas Health Science Center, Houston
Medical College of Wisconsin
Oregon Health and Science University
Christiana Care Health Services
San Francisco General Hospital
University of Utah
Carolinas Medical Center
Investigators
Principal Investigator: Steven R Shackford, MD Scripps Health
  More Information

No publications provided

Responsible Party: Scripps Health
ClinicalTrials.gov Identifier: NCT01890044     History of Changes
Other Study ID Numbers: IRB-11-5786
Study First Received: June 26, 2013
Last Updated: February 20, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Scripps Health:
VTE
DVT
Venous Thromboembolism
Deep Vein Thrombosis
Pulmonary embolus
Trauma

Additional relevant MeSH terms:
Pulmonary Embolism
Thromboembolism
Thrombosis
Venous Thromboembolism
Venous Thrombosis
Cardiovascular Diseases
Embolism
Embolism and Thrombosis
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014